Dolutegravir and central nervous system side-effects: abacavir, older age increase the risk
Some of the Americans who need PrEP the most face the greatest barriers to getting it
Two-drug HIV therapy just as effective as three-drug therapy
As PrEP knowledge increases in San Francisco, 12,500 people now thought to be on PrEP
New $90-$90-$90 target needed for global viral hepatitis, HIV and TB treatment
New HIV prevention products will need marketing and effective health services to reach the people who need them
Huge diversity in current HIV vaccine research, Research for Prevention conference hears
Launch of About HIV / Pro VICH website
